Document:

<PAGE>

                                                                    Exhibit 10.4

         [CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS
AGREEMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE
COMMISSION.]

         THIS AGREEMENT is effective as of the 23rd day of December 1998, by and
between UNIVERSITY OF EDINBURGH operating through its CENTRE FOR GENOME
RESEARCH, of King's Buildings, West Mains Road, Edinburgh EH9 3JQ, United
Kingdom (the "Licensor"), and DELTAGEN, INC., a corporation organized under the
laws of the State of Delaware and having its principal offices at 1031 Bing
Street, San Carlos, California 94070 U.S.A. (the "Licensee").

         A.       WHEREAS, Licensor owns or has rights in certain technology
regarding vectors and the capturing of genes.

         B.       WHEREAS, Licensor wishes to grant, and the Licensee wishes to
receive, an exclusive worldwide license under Licensor's rights in such
technology to research, develop and commercialize technology and products.

         NOW, THEREFORE, in consideration of the foregoing premises and the
mutual covenants herein contained, the parties agree as follows:

         1.       DEFINITIONS AND INTERPRETATION.

         In this Agreement and in the Recitals, unless the context otherwise
requires, the following words and expressions have the following meanings:

         1.1      "Affiliate" means, with respect to any Person, any other
Person which directly or indirectly controls or is controlled by or is under
common control with a Party to this Agreement.

         1.2      "***Product" means a product which incorporates *** that ***
to either (a) *** to prevent the ***, or ***, or (b) ***to prevent the *** into
the *** copy of the ***; in each case, solely to the extent that such *** (x)
were directly developed from the practice of any process or method claimed in
the Patents or (y) contains a composition of matter claimed in the Patents, and
(z) are covered by one or more Valid Claims.

         1.3      "Cell Line Product" means any cell line that (a) is directly
developed from the practice of any process or method claimed in the Patents or
(b) contains a composition of matter claimed in the Patents, and (c) is covered
by one or more Valid Claims.

         1.4      "Centre" means the Centre for Genome Research of the
University of Edinburgh and includes any Person who becomes, in whole or in
part, its successor, substitute or assignee (which includes a Person taking by
way of novation).

  *** Confidential material redacted and separately filed with the Commission.

<PAGE>

         1.5      "Confidential Information" means, with respect to a party, all
information of any kind whatsoever (including without limitation, compilations,
data, formulae, models, patent disclosures, procedures, processes, projections,
protocols, results of experimentation and testing, specifications, strategies
and techniques), and all tangible and intangible embodiments thereof of any kind
whatsoever (including without limitation, apparatus, biological or chemical
materials, animals, cells, compositions, compounds, documents, drawings,
machinery, patent applications records, reports), which is owned or controlled
by such party, is disclosed by such party to the other party pursuant to this
Agreement, and (if disclosed in writing or other tangible medium) is marked or
identified as confidential at the time of disclosure to the receiving party or
(if otherwise disclosed) is identified as confidential at the time of disclosure
to the receiving party and described as such in writing within thirty (30) days
after such disclosure.

         1.6      "Control" means ownership, directly or though one or more
Affiliates, of more than fifty percent (50%) of the shares of stock entitled to
vote for the election of directors, in the case of a corporation, or more than
fifty percent (50%) of the equity interests in the case of any other type of
legal entity, or any other arrangement whereby a party controls or has the right
to control the Board of Directors or equivalent governing body of a corporation
of other entity.

         1.7      "Diagnostic Product" means any product which is used in the
diagnosis and monitoring of any disease, state, trait or condition in humans,
and which contains a product that (x) was directly developed from the practice
of any process or method within the Licensed Technology or (y) incorporates a
composition of matter claimed within the Licensed Technology, and (z) is covered
by one or more Valid Claims.

         1.8      "Discovered Gene" means any gene directly discovered through
the practice of a process or method within the Licensed Technology and which is
covered by one or more Valid Claims.

         1.9      "Discovered Gene Information" means the *** information with
respect to a Discovered Gene.

         1.10     "Drug Product" means a product used in the prevention or
treatment of any disease, condition or state (but excluding traits) in humans
that (a) is a *** and (b) contains a product that (i) was directly developed
from the practice of any process or method within the Licensed Technology or
(ii) incorporates a composition of matter claimed within the Licensed
Technology, and (iii) is covered by one or more Valid Claims; provided however,
that a Drug Product shall not include an *** Product, a *** Product, a ***
Product or a *** Product.

  *** Confidential material redacted and separately filed with the Commission.

<PAGE>

         1.11     "Field" means the use of *** in *** biology *** relating to
genes.

         1.12     "First Commercial Sale" means with respect to any Product, the
first sale for use or consumption by the general public of such Product.

         1.13     "Gene Therapy Product" means any product that (a) *** (which
*** is then introduced into a human host) in order to *** to treat, correct or
modify (as the case may be) a genetic disease, trait or condition and (b)
contains a product that (i) was directly developed from the practice of any
process or method within the Licensed Technology or (ii) incorporates a
composition of matter claimed within the Licensed Technology, and (iii) is
covered by one or more Valid Claims.

         1.14     "Gene Knockout Database Information Product" means a database
product which primarily contains genotypic or phenotypic information with
respect to gene knockouts and which incorporates Discovered Gene Information.

         1.15     "Gene Knockout Database Information Product Representation
Fraction" means the relative percentage representation of the *** in a Gene
Knockout Database Information Product in relation to all other gene
information contained in such Gene Knockout Database Information Product ***,
where *** in the Discovered Gene Information and *** in such Gene Knockout
Database Information Product; provided however, that the Gene Knockout
Database Information Product Representation Fraction shall not be equal to a
value less than ***.

         1.16     "Information and Know-How" means all information, data and
know-how relating to the Field, owned by or licensed to the Licensor prior to or
during the term of this Agreement, which is not generally known including, but
not limited to, formulae, sequences, procedures, protocols, methods, techniques,
compositions, expertise, practice, experience, skill, technical knowledge and
results of experimentation and testing, which are necessary or useful for
Licensee to perform research, development or commercialization on a Product, or
to make, use, sell, offer for sale, or import a Product, or to practice the
methods and processes or make or use any compositions under the Patents.

         1.17     "Inventions" means and includes all patentable and
unpatentable inventions, discoveries, data, information, compositions, methods,
techniques, technology and other results, relating to the Field,

                  (a)      possessed, created, invented, developed or acquired
         by the Licensor or jointly by the Licensor and the Licensee prior to
         the date of this Agreement; or

                  (b)      possessed, created, invented, developed or acquired
         by the Licensor (or licensed to the Licensor) or jointly by the
         Licensor and the Licensee during the term of this Agreement.

  *** Confidential material redacted and separately filed with the Commission.

<PAGE>

         1.18     "Improvement" means any improvement, addition, enhancement,
information, know-how, modification, development, invention, alteration or
technical advance in or relating to any Patent, Invention or Information and
Know-How (whether patentable or not) created, invented, developed or acquired by
the Licensor (or licensed to the Licensor) or jointly by the Licensor and the
Licensee during the term of this Agreement, in which the Licensor has an
ownership or licensable interest prior to the date of this Agreement or during
the term of this Agreement.

         1.19     "Licensed Technology" means Improvements, Inventions,
Information and Know-How and Patents.

         1.20     "Net Sales Price" means, with respect to any Product, the
actual net selling price determined from gross invoiced sales of the Products to
customers, less (a) all discounts, credits, allowances, returns and rebates to
and chargebacks from the account of such customers, (b) transportation charges,
freight, packaging costs and insurance costs incurred with respect to such
Product, (c) cash, quantity and trade discounts and other price reductions, (d)
sales, use, value-added and other taxes directly based on sale and/or time of
payment, (e) customs duties, surcharges and other governmental charges incurred
in connection with exportation or importation of such Product, (f) the cost to
Licensee of the *** which accompany such Product as it is sold, (g) the *** with
respect to such Product, and (h) the *** costs with respect to such Product.

         1.21     "Organism Product" means any *** that (a) is directly
developed through the use of the Licensed Technology and (b) is covered by one
or more Valid Claims.

         1.22     "Parties" means the Licensor and the Licensee, and "Party"
means either of the Licensor or the Licensee.

         1.23     "Patents" means :

                  (a)      (i)      Patent number 5,767,336 granted in the
                  United States of America entitled "Gene Trap Vectors
                  Comprising a Type II Transmembrane Domain", issued August 4,
                  1998;

                           (ii)     Patent number 5,789,653 granted in the
                  United States of America entitled "Secretary Gene Trap",
                  issued June 16, 1998;

                           (iii)    Patent number 673,650 granted in Australia
                  entitled "Novel Vectors and Use Thereof for Capturing Target
                  Genes", issued March 4, 1997;

  *** Confidential material redacted and separately filed with the Commission.

<PAGE>

                           (iv)     *** in Canada entitled "Novel Vectors and
                  Use Thereof for Capturing Target Genes"; and

                           (v)      *** in Japan entitled "Novel Vectors and Use
                  Thereof for Capturing Target Genes" (all of the foregoing,
                  collectively, the "Original Patents");

                  (b)      all patents that have issued or in the future issue
         from such Original Patents and all present and future patents granted
         on patent applications filed in any part of the Territory which
         correspond or relate to any of the Original patents (including without
         limitation, utility and design patents, certificates of invention,
         invention disclosures and statutory invention registrations);

                  (c)      all present and future patents or patent applications
         which claim any Improvements, Inventions, or Information and Know-How,
         filed in any part of the Territory; and

                  (d)      all divisionals, continuations, continuations in
         part, supplemental disclosures, renewals, reissues and extensions to
         any of the foregoing in subparagraphs (a) through (c) above, together
         with any and all patent applications relating to any of them.

         1.24     "Product" means collectively, the *** Products, Cell Line
Products, Diagnostic Products, Drug Products, Gene Knockout Database Information
Products, Organism Products and Therapeutic Protein Products.

         1.25     "Recovery Date of Research, Development and Commercialization
Expenses" means with respect to each Product, the date, *** with respect to such
Product, upon which the Licensee has recovered all costs and expenses relating
to research, development and commercialization of such Product, including
without limitation, labor, materials, Third Party royalty fees, overhead, patent
and attorneys' fees and costs, marketing, advertising and other
commercialization fees and costs with respect to such Product.

         1.26     "Royalty" means the royalty to be paid by the Licensee to the
Licensor pursuant to Section 3.1 below.

  *** Confidential material redacted and separately filed with the Commission.

<PAGE>

         1.27     "Royalty Term" means, with respect to each Product in each
country, (a) if the manufacture, use or sale of such Product in such country was
at the time of the First Commercial Sale in such country covered by a Valid
Claim, the term for which such Valid Claim remains in effect and would, if in an
issued patent, be infringed but for the license granted by this Agreement, or
(b) otherwise, ten (10) years from the date of the First Commercial Sale of such
Product in such country.

         1.28     "Sublicense" means any sublicense to Licensee's rights under
the Licensed Technology granted by the Licensee pursuant to Section 2.1(b).

         1.29     "Territory" means the entire world.

         1.30     "Therapeutic Protein Product" means a product which (a) is
used in the *** of any disease, state or condition in humans, (b) is a *** and
(c) contains a *** that (i) was directly developed from the practice of any
process or method within the Licensed Technology and (ii) is covered by one or
more Valid Claims; provided however, that in the event that such cDNA is not
covered by one or more Valid Claims, such product shall be a "Non-Valid Claim
Therapeutic Protein Product; and provided further, that a Therapeutic Protein
Product shall exclude Gene Therapy Products and *** Products. For purposes of
the definition of Therapeutic Protein Product, a *** shall include *** derived
from a *** that (x) was directly developed from the practice of any process or
method within the Licensed Technology and (y) is covered by one or more Valid
Claims.

         1.31     "Third Party' means any Person other than Licensor, Licensee
and their respective Affiliates.

         1.32     "Valid Claim" shall mean either a claim of an issued and
unexpired patent included within the Patents, which has not been held
permanently revoked, unenforceable or invalid by a decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed within
the time allowed for appeal, and which has not been admitted to be invalid or
unenforceable through reissue or disclaimer or otherwise.

  *** Confidential material redacted and separately filed with the Commission.

<PAGE>

         INTERPRETATION

                  (a)      A reference to a "Person" shall mean a natural person
         or individual, corporation, partnership, limited liability company,
         trust, business trust, association, joint stock company, joint venture,
         pool, syndicate, sole proprietorship, unincorporated organization,
         governmental authority, incorporated association, statutory
         corporation, the Crown and any other type of entity not specifically
         listed herein; words including singular number will include a plural
         number and vice versa; words including a gender will include all other
         genders;

                  (b)      A reference in this Agreement to statute or a section
         of a statute includes all amendments to that statute or section passed
         in substitution for the statute or section referred to or incorporating
         any of its provisions;

                  (c)      Section headings have been inserted for the purpose
         of guidance only, and will not be part of this Agreement;

                  (d)      A reference to a Recital, Article or Section is a
         reference to a recital, article or section of this Agreement;

                  (e)      A reference to a Person includes that Person's
         personal representatives, successors and permitted assigns;

                  (f)      "Agreement" means this license agreement.

         2.       GRANT OF LICENSE.

         2.1      EXCLUSIVE LICENSE TO LICENSEE

         In consideration of the payment of the Royalty set forth in Section 3.1
below, the Licensor hereby grants to the Licensee:

                  (a)      an exclusive license in the Territory under the
         Licensed Technology to conduct research on, develop and commercialize
         the Licensed Technology, to manufacture, have manufactured, use and
         have used, market, sell, have sold, offer for sale, have offered for
         sale, import and export and have imported and exported the
         compositions, technology or inventions, and to practice (or practise)
         the processes or methods that are within or that constitute the
         Licensed Technology for use in the Field.

                  (b)      the right to grant Sublicenses (with the right of
         such sublicensees to grant further sublicenses) to any of the rights
         referred to in paragraph (a) of this Section 2.1 to Affiliates and
         Third Parties, PROVIDED THAT, (a) any such Sublicense is on terms not
         inconsistent with the Licensor's rights under this Agreement and (b)
         Licensee shall be obligated to make the payments required by Section
         3.1(b).

<PAGE>

         2.2      NOTIFICATION AND COPIES OF SUBLICENSES.

         The Licensee will notify the Licensor of the name and address of each
sublicensee promptly upon the Licensee entering into a Sublicense with such
sublicensee and provide to the Licensor a copy of each such Sublicense within
thirty (30) days of the execution and delivery by Licensee and the relevant
sublicensee of such Sublicense.

         2.3      CONTENTS OF SUBLICENSES.

         The Licensee will ensure that provisions materially similar to Sections
3.4, 3.10, 3.11, 3.12, 3.13, 14.1 and Article 9 are incorporated in each
Sublicense.

         2.4      EXPLOITATION OF LICENSE.

         The Licensee, at its expense, will use its commercially reasonable
endeavors, subject to the exercise of its commercially reasonable business
judgment, to commercialize and exploit the Original Patents and to
commercialize, exploit and sell Products, or to appoint sublicensees for the
purpose of such commercialization, exploitation and sale. Notwithstanding this
Section 2.4, the Licensor acknowledges that the Licensed Technology, as of the
date of this Agreement, may not be at a stage which is capable of
commercialization or exploitation. The Licensor further acknowledges that it may
be necessary for the Licensee to conduct and engage in extensive research,
development and commercialization efforts in relation to the Licensed Technology
before the Licensee can fulfill its obligations under this Section 2.4, and that
it cannot be determined at this time whether and to what extent the Licensed
Technology can be commercialized or exploited or Products can be commercialized,
exploited and sold.

         2.5      AVAILABILITY OF THE LICENSED TECHNOLOGY.

         Licensor shall provide Licensee with all information available to
Licensor regarding the Licensed Technology. Licensor shall provide such
technical assistance to Licensee as Licensee reasonably requests regarding the
Licensed Technology.

         2.6      OPTION FOR FUTURE TECHNOLOGY LICENSES TO LICENSEE.

         If during the term of this Agreement:

                  (a)      the Licensor becomes aware that a laboratory, of a
         department or unit of the Licensor, other than the Centre (the "Other
         Department") has developed or is developing technology (the "***
         Technology") which is useful or applicable in ***; or

                  (b)      the Licensor chooses to make available to a Third
         Party the Licensor's technology in an area which is *** (the "Other
         Technology"),

         the Licensor will in each circumstance referred to in subparagraphs (a)
         or (b), promptly notify the Licensee of the availability of such
         technology, providing a reasonably written detailed description of such
         technology, and Licensee shall have an exclusive option for a

<PAGE>

         *** period following the date of such written notice (the "***"), to
         obtain an exclusive, irrevocable, worldwide, royalty-bearing license
         (with the right to sublicense), under the Licensor's patent rights
         and know-how, to practice (or practise) the processes and methods
         and to make, use, sell, offer for sale, import, develop and
         commercialize such *** Technology or the Other Technology, as the
         case may be, ***. Licensor shall provide Licensee with such
         information as is reasonably required by Licensee to evaluate such
         technology. If the Licensee notifies the Licensor in a timely manner
         within the *** Period that the Licensee wishes to obtain such
         license to such *** Technology or Other Technology, the Licensee and
         the Licensor shall, within *** of Licensee's notice to Licensor,
         promptly enter into exclusive negotiations regarding the terms and
         conditions of such license agreement in good faith, and enter into
         such license agreement with respect to such *** Technology or Other
         Technology on the terms described above. The Licensee will be under
         no obligation to accept such offer of a license or to exercise its
         right to obtain a license under this Section 2.6. If Licensee timely
         provides notice to Licensor within the ***, but elects not to obtain
         a license under this Section 2.6, then for a period of ***
         commencing on the date on which Licensee receives the Licensor's
         written notification of disclosure with respect to such ***
         Technology or Other Technology, before the Licensor may offer to a
         third party the opportunity to obtain a license with respect to such
         *** Technology or Other Technology on terms more favorable than
         those offered to Licensee, the Licensor shall first offer each such
         license opportunity to Licensee on such more favorable terms.
         Licensee shall have sixty (60) days within which to accept or reject
         each such offer.

         3.       ROYALTY.

         3.1      ROYALTY.

         In consideration of the licenses granted in Article 2, the Licensee
shall pay to the Licensor during the Royalty Term:

                  (a)      subject to the provisions of Article 4, a royalty of:

                           (i)      five percent (5%) *** in the Territory;

                           (ii)     one percent (1%)*** in the Territory;

                           (iii)    one percent (1%) *** in the Territory;

                           (iv)     one percent (1%) *** in the Territory;

  *** Confidential material redacted and separately filed with the Commission.

<PAGE>

                           (v)      *** in the Territory;

                           (vi)     *** in the Territory;

                           (vii)    *** in the Territory; PROVIDED HOWEVER, that
                  such royalty amount shall ***;

                           (viii)   *** in the Territory;

                           (ix)     *** in the Territory; and

                  (b)      *** For the avoidance of doubt it is agreed that
         royalties and "sublicensing fees" for the purpose of this Section
         3.1(b) ***

         3.2      THIRD PARTY ROYALTIES.

         In the event that Licensee, its Affiliates or sublicensee is required
to pay royalties ("Third Party Royalties") to any Third Party in any country in
order to exercise its rights under this Agreement to manufacture, use, sell,
offer for sale, import, commercialize or sublicense any Product or a technology
which embodies, utilizes, incorporates, requires, or is produced, processed or
otherwise manufactured with or infringes a Third Party technology right or an
intellectual property right, *** under this Article 3 with respect to sales of
such Product in such country; PROVIDED HOWEVER, that ***

         3.3      COMBINATION PRODUCT.

         In the event that one or more Products are sold in combination with one
or more other active or material components (a "Combination Product"), the Net
Sales Price, for purposes of determining Royalties on such Combination Product,
***. In the event that no such separate sales are made by Licensee, its
Affiliates or its sublicensees, the Net Sales Price for royalty determinations
shall be calculated by ***.

  *** Confidential material redacted and separately filed with the Commission.

<PAGE>

         3.4      STATEMENTS WITH ROYALTIES.

         During the term of this Agreement following the First Commercial Sale
of a Product and following the Recovery of Research, Development and
Commercialization Expenses, Licensee shall furnish to Licensor a quarterly
written report showing in reasonably specific detail the items set forth below.
Reports shall be due on the ninetieth (90th) day following the close of each
quarter. Licensee shall keep complete and accurate records in sufficient detail
to properly reflect all gross sales and Net Sales and to enable the royalties
payable hereunder to be determined. Each such quarterly statement shall contain
the following information:

                           (i)      the gross sales of each category of Products
                  sold by Licensee or its Affiliates during the reporting period
                  and the calculation of the Net Sales Price of each category of
                  Products sold by Licensee or its Affiliates from such gross
                  sales;

                           (ii)     the royalties payable, if any, which shall
                  have accrued hereunder based upon the Net Sales of each
                  Product;

                           (iii)    the withholding taxes, if any, required by
                  law to be deducted in respect of such sales; and

                           (iv)     the royalties payable, if any, which shall
                  have accrued hereunder based upon the royalties received from
                  Licensee's sublicensees for such sublicensees' sales of
                  Products.

         3.5      PAYMENT OF ROYALTY.

         The Licensee will pay the royalties shown to have accrued by each
royalty report provided for under Section 3.4 on the date such royalty report is
due. Payment of royalties in whole or in part may be made in advance of such due
date.

         3.6      CURRENCY AND EXCHANGE RATE.

         Each royalty payment provided for under this Agreement shall be paid in
United States dollars. With respect to sales of Products invoiced in United
States dollars, the gross sales, Net Sales, and royalties payable shall be
expressed in United States dollars. With respect to sales of Products invoiced
in a currency other than United States dollars, the gross sales, Net Sales and
royalties payable shall be expressed in the domestic currency of the party
making the sale together with the United States dollar equivalent of the royalty
payable. The United States dollar equivalent shall be calculated using the
average exchange rate (local currency per US$1) published in THE WALL STREET
JOURNAL, Western Edition, under the heading "Currency Trading," on each of the
last business days of each month during the applicable royalty period.

         3.7      EXCHANGE CONTROL.

<PAGE>

         If at any time legal restrictions prevent the prompt remittance of part
or all royalties with respect to any country in the Territory where the Product
is sold, Licensee shall have the right, in its sole discretion, to make such
payments by depositing the amount thereof in local currency to Licensor's
account in a bank or other depository institution in such country. If the
royalty rate specified in this Agreement should exceed the permissible rate
established in any country, the royalty rate for sales in such country shall be
adjusted to the highest legally permissible or government-approved rate.

         3.8      TAXATION ON ROYALTIES.

                  (a)      All income or withholding taxes levied in accordance
         with the tax laws in any country within the Territory on the Royalty
         payments to be made by the Licensee under this Agreement ***.

                  (b)      *** the amount of any withholding taxes, value-added
         taxes or other taxes, levies or charges with respect to such amounts,
         payable by Licensee, its Affiliates or sublicensees, or any taxes
         required to be withheld by Licensee, its Affiliates or sublicensees, to
         the extent Licensee, its Affiliates or sublicensees pay to the
         appropriate governmental authority ***.

                  (c)      The Licensee will furnish the Licensor with tax
         receipts or other certificates issued by the competent taxation office
         showing the payment (if any) by Licensee of such taxes, levies or other
         charges.

         3.9      *** No royalty shall be payable by a sublicensee based upon
such sublicensee's licensing, making, using, offering for sale, importing or
sale of a product or service derived from such sublicensee's use ***.

         3.10     AUDITING STATEMENTS.

         Any statement provided under Section 3.4 will, if reasonably required
by the Licensor, be certified as correct by the Chief Financial Officer of the
Licensee, or if the Licensee does not have a Chief Financial Officer, by a
Person reasonably approved by the Licensor for this purpose, in each case, to
the actual knowledge of such Officer or Person.

  *** Confidential material redacted and separately filed with the Commission.

<PAGE>

         3.11     RECORDS.

         The Licensee shall maintain for a period of three (3) years separate
and accurate records and accounts of the manufacture and sale of the Products,
the Net Sales of such Products, and any other information reasonably required by
the Licensor relevant to the products manufactured and sold and the
determination of Net Sales. Such separate and accurate records and accounts
shall be in reasonably sufficient detail.

         3.12     AUDITING OF RECORDS.

         The Licensee will upon reasonable notice and during ordinary business
hours, permit and give all reasonable assistance to an independent certified
public accounting firm of nationally recognized standing, selected by Licensor
and reasonably acceptable to Licensee, at Licensor's cost, to have access on a
confidential basis to all or any of such records required to be maintained by
the Licensee under Section 3.11 as may be reasonably necessary to verify the
accuracy of the royalty reports hereunder for any year not ending more than
twenty-four (24) months prior to the date of such report. The accounting firm
shall disclose to Licensee only whether the reports are correct or not and the
specific details concerning any discrepancies. No other information shall be
shared.

         3.13     AUDITING OF SUBLICENSEES' RECORDS.

         The Licensee will (to the extent possible), if reasonably requested by
the Licensor, at Licensor's cost, audit such records kept by any sublicensee
pursuant to any Sublicense under this Agreement for the purpose of verifying
Royalty payments made by the Licensee to the Licensor.

         3.14     CONFIDENTIAL FINANCIAL INFORMATION.

         Licensor shall treat all financial information subject to review under
this Article 3 as confidential, and shall cause its accounting firm to retain
all such financial information in confidence under Article 9 below.

         4.       MINIMUM ROYALTY.

         During the Royalty Term and ***, the Licensee shall pay to the Licensor
a minimum annual royalty equal to the Minimum Royalty Amount as set forth below
in this Article 4. If during (a) the period commencing on the First Commercial
Sale and ending on the first anniversary date of such First Commercial Sale or
(b) any subsequent anniversary period thereafter during the Royalty Term, the
aggregate amount of Royalties paid to the Licensor under this Agreement is less
than *** (the "Minimum Royalty Amount"), the Licensee shall, within sixty (60)
days of the end of such anniversary period, pay to the Licensor the *** paid in
a year against the royalties payable to the Licensor under Article 3 above and
Licensor shall have the further *** credits which remain unused in any royalty
period to the following year.

  *** Confidential material redacted and separately filed with the Commission.

<PAGE>

         5.       PATENT APPLICATION.

         5.1      PATENT PROSECUTION.

         During the term of this Agreement, the Licensor and the Licensee will
reasonably consult and cooperate together on actions to be taken with regard to
filing and the prosecution of patent applications in the Territory with respect
to the Licensed Technology. Licensee shall have the right (but not the
obligation) to control, at its sole cost and discretion, the preparation,
filing, prosecution and maintenance of all patents and patent applications
related to the Licensed Technology in each country within the Territory, unless
the parties otherwise agree. If Licensee elects not to control the preparation,
filing, prosecution or maintenance of a patent or patent application for the
Licensed Technology in any country within the Territory, the Licensor shall then
have the right to do so. Licensee shall give Licensor an opportunity to review
and comment on the text of each patent application subject to this Section 5.1
before filing, and shall supply Licensor with a copy of such patent application
as filed, together with notice of its filing date and serial number.

         5.2      PATENTS IN NAME OF LICENSOR.

         Unless otherwise agreed in writing between the Parties, or unless
otherwise required by the legislation of a particular country in which a patent
application in respect of any Licensed Technology may be made, all patents
solely developed, created or invented by the Licensor (except for patents on
jointly owned inventions, which will be jointly owned by the parties and
prosecuted in the joint names of the Licensor and Licensee) will be solely owned
by the Licensor and will be prosecuted in the name of the University and the
Parties will make all reasonable efforts to ensure that all documents and things
are executed and done by Parties or their employees, agents or representatives
to secure the grant of such patents in the name of the Licensor.

         5.3      DUE DILIGENCE IN PROSECUTING APPLICATIONS.

         Each Party will use all reasonable efforts and exercise due diligence
in prosecuting any patent application under Section 5.1 in full accordance with
all the relevant laws and requirements of the country concerned and each will
keep the other informed of all official actions and responses arising out of the
prosecution of such patent application.

         5.4      COSTS OF PATENT PROSECUTION.

         For so long as the Licensee retains the exclusive license granted under
Section 2.1 during the term of this Agreement, the Licensor will have the right
to seek reimbursement from the Licensee of all reasonable patent application
prosecution expenses it may incur after the date of this Agreement in connection
with the prosecution of any patent application under the Licensed Technology in
the Territory, unless the Licensee notifies the Licensor in writing of
Licensee's intention not to include such patent application to which such
expenditure may relate under the

<PAGE>

Licensed Technology; PROVIDED, HOWEVER, that any such expenses in excess of
$5,000 in any year shall require the prior written approval of Licensee.

         5.5      PARTIES TO ASSIST IN PROSECUTION.

         The Licensor and the Licensee each agree to give the other all
assistance (including the execution of all lawful papers and instruments, the
making of all rightful oaths and declarations and the taking of all actions) as
may be reasonably necessary in the preparation, filing, prosecution or
maintenance of all patents, patent applications and filings under this Article
5.

         6.       REGISTRATION.

         During the term of this Agreement, the Licensor, at the request of the
Licensee, shall execute all lawful papers and instruments, make all rightful
oaths and declarations and take all reasonable actions, to enable the Licensee
at its expense, to become duly registered, licensed or otherwise legally
designated in any country in the Territory, as an exclusive licensee under the
Licensed Technology.

         7.       LICENSEE'S ENHANCEMENTS.

         7.1      LICENSEE'S ENHANCEMENTS PROPERTY OF LICENSEE.

         All inventions, enhancements and improvements to the Original Patents
or the Licensed Technology, originated developed, created, discovered or
invented by the Licensee, and all unpatentable and patentable inventions,
processes, formulae, technical information, compositions, compounds, methods,
expertise, know-how, practice, experience, skill and technical knowledge
relating to the Field which is originated, developed, created, discovered or
invented by the Licensee (collectively, the "Licensee's Technology") shall be
solely owned by the Licensee and all right, title and interest thereto and
therein shall vest in and be the exclusively property of the Licensee.

         7.2      NON-EXCLUSIVE LICENSE OF LICENSEE'S TECHNOLOGY TO LICENSOR.

         In consideration for the licenses granted by the Licensee to the
Licensor hereunder, during the term of this Agreement, the Licensor shall have
the right to negotiate with the Licensee for a Licensor during the term of this
Agreement a nontransferable, nonassignable, non-sublicensable, nonexclusive
license under the Licensee's Technology for the sole purpose of conducting
non-commercial, internal research in the Field at the Licensor's facilities.

         8.       STANDARDS OF MANUFACTURE AND LABELING.

         8.1      COMPLIANCE WITH STANDARDS.

         The Licensee will use all reasonable efforts to manufacture the
Products according to the requirements and specifications of any reasonably
applicable standards set forth by the country and the part of the Territory
where the particular Product is to be sold and the Licensee shall use

<PAGE>

all reasonable efforts to not sell any Products that do not meet such
specifications and requirements.

         8.2      INDEMNITY.

         Except as provided in Section 10.2, the Licensee shall indemnify the
Licensor against all liabilities, damages, costs or expenses, including
reasonable attorneys' fees and costs, in respect of all claims, demands,
actions, proceedings or prosecutions which may be brought, commenced or
prosecuted against the Licensor by a Third Party, relating to or arising out of
the manufacture, sale or commercial utilization of the Products by Licensee, its
Affiliates and its sublicensees.

         8.3      INSURANCE.

         In the event that insurance is available at commercially reasonable
rates, the Licensee will at all times following the First Commercial Sale of a
Product, maintain and keep current in respect of the Licensee's manufacture and
sale of the Products, product liability insurance obtained from a reasonably
reputable insurer and shall make available to the Licensor such policy for
inspection upon reasonable request by the Licensor.

         9.       SECRECY OBLIGATIONS.

         9.1      CONFIDENTIALITY.

         Subject to Section 9.2, during the term of this Agreement and for five
(5) years thereafter, each Party undertakes to the other Party to maintain in
confidence and not disclose to any third party all Confidential Information of
the other party and to ensure that its employees, agents, contractors,
subcontractors, solicitors and other advisers keep the Confidential Information
confidential and do not disclose it to any third party.

         9.2      EXCEPTIONS.

                  A Party (the "Recipient") may reveal Confidential Information
                  of the other Party (the "Provider") which the Recipient
                  establishes:

                  (a)      is required by law to be revealed, provided that the
         Recipient immediately notifies the Provider of the requirement and
         takes lawful steps to permit the Provider with an opportunity to oppose
         or restrict such disclosure to preserve as far as possible the
         confidentiality of the Confidential Information;

                  (b)      is in or enters the public domain other than through
         a breach of this Agreement; or

                  (c)      is revealed to a sublicensee under a sublicense which
         complies in all respects with the provisions of this Agreement
         including, without limitation, the provisions of Section 2.3; and

<PAGE>

                  (d)      was known to the Recipient before its disclosure by
         the provider;

                  (e)      is furnished to the Recipient by a third party
         legally entitled to furnish such information and not under an
         obligation of confidentiality to the Provider; or

                  (f)      was independently developed by employees or agents of
         the Recipient without access to or use of such information disclosed by
         the Provider to the Recipient.

         9.3      DISCLOSURE OF TERMS AND CONDITIONS OF THIS AGREEMENT.

         Except as otherwise provided in Section 9.2 above, Licensor and
Licensee shall not disclose any terms or conditions of this Agreement to any
Third Party without the prior consent of the other party, PROVIDED THAT, either
party may disclose the terms and conditions of this Agreement in connection with
such party's merger, consolidation, change in control, sale of all or
substantially all its assets, an equity investment in such party by a Third
Party or such party's disclosure obligations pursuant to applicable disclosure
laws, rules or regulations. Notwithstanding the foregoing, prior to execution of
this Agreement, Licensor and Licensee shall agree upon the substance of
information that can be used to describe the terms of this transaction, and
Licensor and Licensee may disclose such information, as modified by mutual
agreement from time to time, without the other party's consent.

         10.      REPRESENTATIONS AND WARRANTIES.

         10.1     BY EACH PARTY. Each party hereby represents and warrants to
the other party as follows:

                  (a)      Such party is duly organized, validly existing and in
         good standing under the laws of the state in which it is organized.

                  (b)      Such party (a) has the power and authority and the
         legal right to enter into this Agreement and to perform its obligations
         hereunder, and (b) has taken all necessary action on its part to
         authorize the execution and delivery of this Agreement and the
         performance of its obligations hereunder. This Agreement has been duly
         executed and delivered on behalf of such party, and constitutes a
         legal, valid, binding obligation, enforceable against such party in
         accordance with its terms.

                  (c)      All necessary consents, approvals and authorizations
         of all governmental authorities and other Persons required to be
         obtained by such party in connection with this Agreement have been
         obtained.

                  (d)      The execution and delivery of this Agreement and the
         performance of such party's obligations hereunder (a) do not conflict
         with or violate any requirement of applicable laws or regulations, and
         (b) do not conflict with, or constitute a default under, any
         contractual obligation of it.

<PAGE>

         10.2     BY LICENSOR. The Licensor hereby represents, warrants and
covenants to the Licensee that:

                  (a)      except as may otherwise be expressly notified to the
         Licensee in writing, the Licensor has and for the duration of this
         Agreement, will continue to have full right and title to the Patents,
         the Patent Applications, the Inventions, the Information, the Know-How,
         the Improvements and the Licensed Technology, except to the extent
         co-owned with Licensee;

                  (b)      the Licensor has the right to grant the license and
         sublicense rights under this Agreement to the Licensee and the
         Licensee's sublicensees;

                  (c)      the Licensor is entitled to make all patent
         applications which it has made, and the Licensor has not made knowing
         use of any intellectual property or other rights of any third party in
         the making of the patent applications;

                  (d)      all Patent Applications filed by the Licensor at the
         date of this Agreement have to the best knowledge of the Licensor been
         made in the prescribed form and in the prescribed manner;

                  (e)      the Patents, the Patent Applications, the Inventions,
         the Information, the Know-How and the Improvements include or will
         include all technology owned by or registered in the name of the
         Licensor or to which the Licensor is beneficially entitled on or
         relating to the Field and possessed, invented, developed or acquired by
         or for the Licensor;

                  (f)      all Inventions, Information, Know-How and
         Improvements supplied to the Licensee by the Licensor will be to the
         best of the knowledge and belief of the Licensor true, accurate,
         reliable and up-to-date; and

                  (g)      Licensor (a) is the sole owner or exclusive licensee
         of the Licensed Technology, and except as Licensor has expressly
         informed Licensee in writing prior to the date of this Agreement, has
         not granted to any Third Party any license or other interest in the
         Licensed Technology; (b) is not aware of any Third Party patent, patent
         application or other intellectual property rights that would be
         infringed (i) by practicing any process or method or by making, using
         or selling any composition which is claimed or disclosed in the Patents
         or which constitutes Information and Know-How, or (ii) by making, using
         or selling Products; and (c) is not aware of any infringement or
         misappropriation by a Third Party of the Licensed Technology.

         10.3     INDEMNITY.

         The Licensor will indemnify the Licensee (including its employees,
agents and representatives) throughout the term of this Agreement against legal
liability, and against the costs of any claims or actions arising under this
Agreement to the extent that the liability is directly caused by negligent acts
or by omissions of the Licensor in the carrying out of its

<PAGE>

obligations under this Agreement or is caused by a breach of any warranty,
representation or covenant given by the Licensor under this Agreement.

         11.      FAILURE TO GRANT OR SUBSEQUENT REVOCATION OF TRUST.

         11.1     ROYALTIES TO BE REDUCED.

         If as a result of the *** the Licensee, its Affiliates or any of the
Licensee's sublicensees in such part of the Territory is significantly adversely
affected with regard to the research, development, commercialization,
manufacture, use, import, offering for sale, sale or profitability of a Product,
*** (i) through an order of a court, other governmental or administrative order
(A) against which no appeal can be taken declaring the relevant patents invalid,
unenforceable or otherwise (as the case may be) or (B) refusing to grant or
recognize the relevant Patent, Patent Application or other intellectual property
right under the Licensed Technology becomes final, (ii) through a law,
regulation or statute or (iii) otherwise; PROVIDED HOWEVER, *** if the Licensee
reasonably demonstrates to the Licensor good and sufficient reason for such
reduction.

         11.2     REDUCTION OF ROYALTY GUARANTEE.

         ***, the Royalties payable to the Licensor by Licensee under this
Agreement *** and this Agreement shall be deemed automatically amended
accordingly.

         12.      PATENT INFRINGEMENT.

         12.1     NOTIFICATION OF INFRINGEMENT.

         Each party shall notify the other party of any infringement in the
Territory known to such party of any Patents and shall provide the other party
with the available evidence, if any, of such infringement.

         12.2     ENFORCEMENT OF PATENT RIGHTS.

         Licensee, at its sole expense, shall have the right to determine the
appropriate course of action to enforce all intellectual property rights within
the Licensed Technology (including without limitation, any Patent, patent right,
trade secret right, or other right) or otherwise abate the infringement thereof,
to take (or refrain from taking) appropriate action to enforce all intellectual
property rights within the Licensed Technology, to control any litigation or
other enforcement action and to enter into, or permit, the settlement of any
such litigation or other enforcement action with respect to the intellectual
property rights within the Licensed Technology, and shall consider, in good
faith, the interests of Licensor in so doing. If Licensee does not, within one
hundred twenty (120) days of receipt of notice from Licensor, abate the
infringement or file suit to enforce the intellectual property rights within the
Licensed Technology against at least one infringing party in the Territory,
Licensor shall have the right to

  *** Confidential material redacted and separately filed with the Commission.

<PAGE>

take whatever action it deems appropriate to enforce such intellectual property
rights within the Licensed Technology; PROVIDED, HOWEVER, that, within thirty
(30) days after receipt of notice of Licensor's intent to file such suit,
Licensee shall have the right to jointly prosecute such suit and to fund up to
one-half (1/2) the costs of such suit. The party controlling any such
enforcement action shall not settle the action or otherwise consent to an
adverse judgment in such action that diminishes the rights or interests of the
non-controlling party without the prior written consent of the other party. All
monies recovered upon the final judgment or settlement of any such suit to
enforce the intellectual property rights within the Licensed Technology shall be
shared, after reimbursement of expenses, by Licensor and Licensee PRO RATA
according to the respective percentages of costs borne by each in such suit.
Notwithstanding the foregoing, Licensor and Licensee shall fully cooperate with
each other in the planning and execution of any action to enforce the
intellectual property rights within the Licensed Technology.

         12.3     NOTIFICATION.

         In the event either Party asserts a claim or institutes an action as a
result of an actual or apparent infringement of any intellectual property right
within the Licensed Technology, such party will immediately notify the other
party.

         12.4     ASSISTANCE.

         Either Party (the "Cooperating Party") will if required by a Party
asserting a claim or prosecuting an action pursuant to this Article 12 (the
"Asserting Party"), lend its name and will otherwise do all acts and things the
Asserting Party may reasonably require to assist the Asserting Party in
performing its obligations under this Article 12. Without limiting the preceding
sentence, the Cooperating Party will execute all documents and do all things
reasonably necessary to aid and co-operate in the prosecution of any action
bought by the Asserting Party pursuant to Article 12.

         13.      TERMINATION.

         13.1     EXPIRATION.

         Subject to the provisions of Sections 13.2 and 13.3 below, this
Agreement shall expire on the expiration of Licensee's obligation to pay
royalties to the Licensor under Section 3.1 above.

         13.2     TERMINATION BY LICENSOR.

         The Licensor may at any time terminate this Agreement upon the
happening of any of the following events (other than a "Force Majeure Event"):

                  (a)      if an order is made or a resolution passed for the
         winding up or the dissolution without winding up or liquidation of the
         Licensee, provided always that default shall not be deemed to have
         occurred where the winding up, dissolution or

<PAGE>

         liquidation is for the purpose of a reorganization, merger,
         consolidation, reconstruction or amalgamation and the scheme for such a
         reorganization, merger, acquisition, consolidation, reconstruction or
         amalgamation requires the surviving entity to assume all of the
         Licensee's liabilities hereunder;

                  (b)      if default is made by the Licensee in payment of
         Royalty, and where such default is not remedied within ninety (90) days
         after written notice specifying such default and requiring the Licensee
         to remedy the same has been given by the Licensor to the Licensee; or

                  (c)      if material default is made by the Licensee in
         performance or observance of any material provision of this Agreement
         other than a default referred to in subparagraph (b) above, and where
         such default is capable of remedy such default is not remedied within
         one hundred and eighty (180) days after written notice specifying such
         default and requiring the Licensee to remedy the same has been by the
         Licensor to the Licensee.

         13.3     TERMINATION BY LICENSEE.

         The Licensee may at any time terminate this Agreement:

                  (a)      by notice if material default is made by the Licensor
         in the performance or observance of any provision of this Agreement,
         and where such default is capable of remedy such default is not is not
         remedied within ninety (90) days after written notice specifying such
         default and requiring the Licensor to remedy the same has been given by
         the Licensor; PROVIDED HOWEVER, that Licensee shall also have the right
         to elect not to terminate this Agreement and during the period of such
         material default by Licensor under this paragraph (a), any royalties
         payable to Licensor by Licensee shall be reduced by fifty percent
         (50%); or

                  (b)      in its sole discretion, on a Product-by-Product basis
         or otherwise, upon thirty (30) days prior written notice to Licensor.

         14.      EFFECTS OF TERMINATION.

         14.1     EFFECTS OF TERMINATION.

         Upon terminating of this Agreement for any reason whatsoever:

                  (a)      each Party will return to the other Party all of the
         second mentioned Party's Confidential Information in the possession or
         under the control, or in the possession or under the control of the
         servants or agents of the mentioned Party.

                  (b)      subject to paragraph (c) of this Section 14.1 neither
         Party will have any further rights in relation to the other Party's
         Confidential Information whether under common or other law, statute or
         otherwise and, each Party will, at its own expense,

<PAGE>

         execute and deliver to the other Party such instruments and take all
         other action as the other Party deems reasonably necessary to ensure
         the termination of any such rights, and to vest every interest in the
         Confidential Information in the Party owning that Confidential
         Information.

                  (c)      any Sublicense will remain in full force and effect
         provided the sublicensee is not in breach of the Sublicense and
         performs all reasonable actions required by the Licensor to effect a
         novation of the Sublicense to the Licensor;

                  (d)      Sections 3.14, 8.2, 8.3, 10.2, 10.3, 14.1 and
         Articles 9, shall survive any termination or expiration of this
         Agreement;

                  (e)      Section 3 will continue in force and effect until all
         applicable Royalties payable under this Agreement are paid.

         14.2     ACCRUED RIGHTS AND OBLIGATIONS.

         Upon expiration of this Agreement, Licensee shall have a paid-up,
worldwide, royalty-free exclusive license (with the right to grant sublicenses)
under the Licensed Technology to make, use, sell, offer for sale, import,
develop and commercialize Products. Expiration or termination of this Agreement
will not affect any rights or obligations which may have accrued, to either
Party, prior to the date of such termination.

         15.      GENERAL.

         15.1     WAIVER.

         Any waiver or other indulgence by either Party in respect of any
obligation of the other party under this Agreement will operate only if in
writing and will apply only to the specified instance, and will not constitute a
waiver of or an indulgence in respect of any other right or obligation under
this Agreement.

         15.2     ENTIRE AGREEMENT.

         This Agreement constitutes the whole and entire agreement between the
Parties and replaces all previous representations, understandings or
arrangements given or made by the Parties, whether oral or in writing.

         15.3     ASSIGNMENT.

         Neither Party will assign all or any of its rights under this Agreement
without the prior written consent of the other Party, which consent must not be
unreasonably withheld, except that the Licensee may assign its rights without
consent to any party with which it may merge or consolidate or to which it may
transfer all or substantially all of its assets, provided other such party
agrees in writing to assume all of the Licensee's obligations hereunder.

<PAGE>

         15.4     APPLICABLE LAW.

         This Agreement is governed by and to be construed according to the laws
of the State of New York without regard to the conflicts of laws principles
thereof.

         15.5     AMENDMENTS.

         This Agreement may not be varied except in writing signed by the
Parties.

         15.6     SEVERABILITY.

         If any Provision of this Agreement is held by a court to be unlawful,
invalid, unenforceable or in conflict with any rule of law, statute, ordinance
or regulation, the validity and enforceability of the remaining provisions will
not be thereby affected.

         15.7     FORCE MAJEURE.

         Neither Party shall be held liable or responsible to the other party
nor be deemed to have defaulted under or breached this Agreement for failure or
delay in fulfilling or performing any term of this Agreement to the extent, and
for so long as, such failure or delay is caused by or results from causes beyond
the reasonable control of the affected Party, including but not limited to fire,
floods, embargoes, war, acts of war (whether war be declared or not),
insurrections, riots, civil commotions, strikes, lockouts or other labor
disturbances, acts of God or acts, omissions or delays in acting by any
governmental authority or the other Party.

         15.8     NOTICES.

         Any consent, notice or report required or permitted to be given or made
under this Agreement by one of the parties hereto to the other party shall be in
writing, delivered personally or by facsimile (and promptly confirmed by
personal delivery, first class mail (or materially similar mail) or courier),
first class mail or courier, postage prepaid (where applicable), addressed to
such other party at its address indicated below, or to such other address as the
addressee shall have last furnished in writing to the addressor and (except as
otherwise provided in this Agreement) shall be effective upon receipt by the
addressee.

                  If to Licensor:           Centre for Genome Research
                                            University of Edinburgh

                  Address:                  King's Buildings
                                            West Mains Road,
                                            Edinburgh EH9 3JQ,
                                            United Kingdom

                  Facsimile:                (131) 667 0164

                  If to Licensee:           Deltagen, Inc.

<PAGE>

                  Address:                  1031 Bing Street
                                            San Carlos, California 94070

                  Facsimile:                (650) 610-6823

                  (a)      if given by hand, will be deemed to have been given
         on the day it was so delivered;

                  (b)      if given by mail, will be deemed to have been given
         seven clear business days after being sent pre-paid mail;

                  (c)      if given by facsimile, will be deemed to have been
         given on the day on which the facsimile is sent and the sender's
         machine records that the transmission has been received by the
         recipient's facsimile machine and, a hard copy of the relevant notice
         shall be sent to the recipient by first class pre-paid mail within
         twenty-four (24) hours of a successful transmission report by the
         sender's facsimile machine.

         15.9     FURTHER AGREEMENTS.

         Each Party shall execute, acknowledge and deliver such agreements,
deeds and documents and do or cause to be done all such other acts and things as
shall be necessary or appropriate to give effect to this Agreement or to carry
out the purposes and intent of this Agreement.

         15.10    CHARGES.

         All stamp duties and governmental charges arising out of or incidental
to this Agreement (other than charges with respect to the payment of income
taxes by Licensor) shall be the responsibility of and payable by the Licensee.

         IN WITNESS WHEREOF the Parties have executed this Agreement on the date
and in the year first above written.

                                      UNIVERSITY OF EDINBURGH

                                      By: /s/ M.D. Cornish
                                         ---------------------------------------

                                      Name: M.D. Cornish
                                           -------------------------------------

                                      Title: Deputy Secretary
                                            ------------------------------------

                                      DELTAGEN, INC.

<PAGE>

                                      By: /s/ William Matthews, Ph.D.
                                         ---------------------------------------

                                      Name: William Matthews, Ph.D.
                                           -------------------------------------

                                      Title: President and Chief Executive
                                            ------------------------------------<PAGE>

                                                                   EXHIBIT 10.17

CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT
TO THE OMITTED PORTIONS.

                            MASTER SERVICES AGREEMENT

         This Agreement, including all attachments hereto, (this "Agreement") is
entered into as of October 2, 1998 (the "Effective Agreement Date"), by and
between Deltagen, Inc., a Delaware corporation having an address at 1031 Bing
Street, San Carlos, California 94070, and all of its Affiliates (as defined
below) ("DELTAGEN"); and ROCHE BIOSCIENCE, A DIVISION OF SYNTEX (U.S.A.) INC., a
Delaware corporation having an address at 3401 Hillview Avenue, Palo Alto,
California 94304 (as defined below) ("ROCHE BIOSCIENCE").

         WHEREAS, DELTAGEN possesses knowledge and experience in the research
and generation of Knockout Mice (defined below); and

         WHEREAS, ROCHE BIOSCIENCE wishes to engage DELTAGEN to obtain the
benefit of such knowledge and experience with respect to projects being
conducted by ROCHE BIOSCIENCE in research, development or evaluation of various
gene sequences, pharmaceutical compounds or products of ROCHE BIOSCIENCE;

         NOW THEREFORE, in consideration of mutual covenants set forth herein,
DELTAGEN and ROCHE BIOSCIENCE (individually "Party" and collectively "Parties")
agree as follows:

1.       DEFINITIONS.

         1.1      "Affiliate" of a Party shall mean any corporation or other
business entity controlled by, controlling or under common control with, such
Party. For this purpose "control" shall mean direct or indirect beneficial
ownership of more than fifty percent (50%) of the voting or income interest
in such corporation or other business entity.

         1.2      "Budget" means the pricing and payment terms for a Knockout
Mice Project substantially in the form set forth in Attachment II attached
hereto.

         1.3      "Claim(s)"shall have the meaning set forth in Section 12.1
below.

         1.4      "Confidential Information" means with respect to a Party
hereto (the "Disclosing Party"), collectively, all technical, financial and
business information of any kind whatsoever, and all tangible and intangible
embodiments thereof of any kind whatsoever, disclosed by the Disclosing Party
to the other Party hereto (the "Receiving Party") or obtained by the
Receiving Party through observation or examination of the foregoing, but only
to the extent such information or embodiment is maintained, as confidential
by the Disclosing Party and is marked or otherwise identified as confidential
when disclosed to the Receiving Party or, in the case of information given
verbally, is identified as confidential in a written document provided to the
Receiving Party within thirty (30) days after verbal disclosure to the
Receiving Party. For purposes of this Agreement and without limiting the
generality of the foregoing, the Data and the Study materials shall be
considered the Confidential Information of ROCHE BIOSCIENCE.

         1.5      "Data" means all data-or information generated under this
Agreement during a Knockout Mice Project, * * * required to be generated,
collected or analyzed by Deltagen under a Scope of Work.

         1.6      "Deltagen Technology" means all Inventions owned by or
licensed to DELTAGEN for use in the design, creation, development, generation
or production of Knockout Mice.

         1.7      "Designated Site(s)" means the site(s) designated for a
Knockout Mice Project as set forth in the applicable Scope of Work.

         1.8      "Effective Commencement Date" shall have the meaning set
forth in Section 2.3 below.

* * * Confidential material redacted and separately filed with the Commission.

                                       1
<PAGE>

         1.9      "FDA" means the United States Food and Drug Administration.

         1.10     "Inventions" means technology, information, data, know-how,
inventions, improvements and all patent or other intellectual property rights
therein-and thereto.

         1.11     "Knockout Mice (Mouse)" means * * * mice having a Standard
mutation wherein such mice transmit the Standard Mutation, in the form of
* * *, through the germ line.

         1.12     "Knockout Mice (Mouse) Project" means a specific project to
create, test and generate Knockout Mice under this Agreement in accordance
with the terms of a specific Scope of Work.

         1.13     "Law" means any federal, state or local law, rule, or
regulation.

         1.14     "Milestone" shall mean the milestones set forth on the
Scope of Work attached hereto.

         1.15     "Regulatory Agency" means the FDA or any other similar
governmental agency or agencies in countries other than the United States.

         1.16     "Regulatory Filing" means any form or other statement
required to be filed with any Regulatory Agency.

         1.17     "Roche Bioscience Representative" means the representative
identified in writing by ROCHE BIOSCIENCE on a Scope of Work, as such
representative may be changed from time to time

* * * Confidential material redacted and separately filed with the Commission.

                                       2
<PAGE>

         in writing by ROCHE BIOSCIENCE.

         1.18     "Roche Bioscience Technology" means all Inventions and
Study Materials owned by, licensed to or otherwise freely available (without
restriction) to ROCHE BIOSCIENCE and delivered by ROCHE BIOSCIENCE to
DELTAGEN for use or otherwise utilized by DELTAGEN pursuant to this Agreement.

         1.19     "Scope of Work" means a work plan for a Knockout Mice
Project (or other similar document) substantially in the form attached hereto
as Attachment I which references this Agreement and is mutually agreed to in
writing by ROCHE BIOSCIENCE and DELTAGEN.

         1.20     "Standard Mutation" means the interruption or deletion in a
portion of a single, specified gene by * * *.

         1.21     "Study Materials" means any samples or materials (including
chemical or biological) provided by ROCHE BIOSCIENCE to DELTAGEN under this
Agreement for purposes of a Knockout Mice Project, including but not limited
to drugs, compounds, genes, probes, formulations and other substances.

2.       SCOPE OF WORK

         2.1      INDIVIDUAL KNOCKOUT MICE PROJECTS. If ROCHE BIOSCIENCE
wishes DELTAGEN to perform a Knockout Mice Project under this Agreement,
ROCHE BIOSCIENCE and DELTAGEN shall meet and attempt to reach
mutual-agreement upon a Scope of Work for such Knockout Mice Project,
including the applicable technical specifications, budget and a time schedule
for such Knockout Mice Project to be performed pursuant to Attachments I and
II. ROCHE BIOSCIENCE shall initiate a request for a Scope of Work by
notifying DELTAGEN in writing and providing a description of the particular
Knockout Mice Project requested. DELTAGEN shall evaluate each such request to
determine whether such Knockout Mice Project is feasible, if it is otherwise
acceptable to DELTAGEN or if DELTAGEN requires modifications thereto. If such
a Knockout Mice Project, in DELTAGEN's commercially reasonable discretion, is
not feasible or is not otherwise acceptable to DELTAGEN, DELTAGEN shall have
the right (without penalty) to decline to undertake such Knockout Mice
Project. The terms of this Agreement, the Scope of Work and the Budget shall
form the entire agreement of the Parties with respect to each Knockout Mice
Project.

         2.2      INITIATION OF KNOCKOUT MICE PROJECTS. Prior to DELTAGEN's
initiation of each Knockout Mice Project, ROCHE BIOSCIENCE shall:

                  2.2.1    Identify to DELTAGEN in writing each Knockout Mice
Project to be initiated and agree with DELTAGEN upon the Scope of Work for
such Knockout Mice Project;

                  2.2.2    Disclose in writing to DELTAGEN * * * in the
possession of or freely available (without restriction) to ROCHE BIOSCIENCE
that is reasonably necessary or useful for DELTAGEN to * * * to complete
Milestones 1 and 2 under this Agreement with respect to each Knockout Mice
Project.

                  2.2.3    Consult with and agree with DELTAGEN regarding the
* * *;

                  2.2.4    Transfer to DELTAGEN any * * * licensed (without
restriction or cost), owned by or freely available (without restriction) to
ROCHE BIOSCIENCE that may be suitable for * * *; and

                  2.2.5    Identify and notify DELTAGEN in writing of the
specifications (including the specific gene sequence) for each Knockout Mice
Project for which DELTAGEN is requested by ROCHE BIOSCIENCE to produce
Knockout Mice.

         2.3      COMMENCEMENT OF KNOCKOUT MICE PROJECT. Each Knockout Mice
Project conducted hereunder shall commence fifteen (15) days after written
agreement by both parties on a Scope of Work and DELTAGEN's receipt from
ROCHE BIOSCIENCE of all information and materials set forth in Section 2.2
relating to such Knockout Mice project (the "Effective Commencement Date").
ROCHE BIOSCIENCE shall be solely responsible for identifying and notifying
DELTAGEN in writing of the specific gene sequence for each Knockout Mice
Project.

* * * Confidential material redacted and separately filed with the Commission.

                                       3
<PAGE>

         2.4      PERFORMANCE. DELTAGEN shall use its commercially reasonable
efforts to perform its obligations under this Agreement, PROVIDED THAT, ROCHE
BIOSCIENCE acknowledges and agrees that the performance of the Knockout Mice
Projects involves a number of technologically complex steps and that any time
periods for performance are reasonable estimates only and may be subject to
change due to potential technological difficulties encountered. DELTAGEN
shall notify ROCHE BIOSCIENCE of any such technical difficulties as soon as
reasonably practicable after such difficulties are encountered and the
parties shall discuss in good faith methods to resolve such technical
difficulties in a reasonable manner. Except as otherwise set forth in this
Agreement, if DELTAGEN is unable to complete a Milestone under any Scope of
Work for a Knockout Mice Project within the estimated times set forth in the
Scope of Work, ROCHE BIOSCIENCE shall have the right to terminate such
Knockout Mice Project as set forth in Section 11.4.1.

         2.5      COMPLETION OF KNOCKOUT MICE PROJECT. Each Knockout Mice
Project shall be deemed complete upon DELTAGEN's completion of Milestone 3 on
Attachment I for each such Knockout Mice Project ,and DELTAGEN's delivery of
at least * * * for a minimum of * * * and ROCHE BIOSCIENCE's confirmation
* * *.

         2.6      DESIGN BY DELTAGEN. DELTAGEN shall use reasonable efforts
to design, as technically practical, * * * and to generate
Knockout Mice under each Knockout Mice Project according to the
specifications of ROCHE BIOSCIENCE as set forth in Section 2.2 above.

         2.7      ADHERENCE TO SCOPE OF WORK. DELTAGEN shall perform those
activities described in the Scope of Work for each Knockout Mice Project at
the Designated Site, and shall comply with all the terms and requirements of
both this Agreement and the applicable Scope of Work. Neither Party shall
change or deviate from a Scope of Work without the prior written consent of
the other Party. Each party shall devote the necessary level of personnel and
resources to conduct and complete its obligations under this Agreement in a
commercially reasonable manner pursuant to the terms of this Agreement and in
compliance with all applicable laws.

         2.8      CHANGES TO A KNOCKOUT MICE PROJECT. ROCHE BIOSCIENCE may,
from time to time, propose a modification to the terms of a Knockout Mice
Project. If ROCHE BIOSCIENCE intends to change any terms of a Knockout Mice
Project, including but not limited to the time schedule for the work, ROCHE
BIOSCIENCE shall submit such change(s) in writing to DELTAGEN (the "Proposed
Change"). Such Proposed Change shall be implemented by the parties only upon
DELTAGEN's acceptance of such modifications in writing and upon the mutual
agreement of the parties on a revised Budget as set forth in Section 3.2
below. DELTAGEN shall have the right, in its commercially reasonable
discretion, to accept or reject such Proposed Change based upon DELTAGEN's
good faith belief as to whether such change would alter DELTAGEN's technical
or financial obligations under a Scope of Work.

         2.9      STANDARDS OF WORK AND ANIMAL CARE. With respect to each
Knockout Mice Project, DELTAGEN shall comply with all applicable * * * and
good industry standards regarding the maintenance and care of the Knockout
Mice. Prior to delivery to ROCHE BIOSCIENCE, * * *. DELTAGEN warrants that
the Knockout Mice delivered to ROCHE BIOSCIENCE under this Agreement shall be
in good health * * *. DELTAGEN shall replace any Knockout Mice that arrive at
ROCHE BIOSCIENCE diseased or dead (except for disease or death resulting from
the actions of ROCHE BIOSCIENCE's designated carrier). Upon the reasonable
request of ROCHE BIOSCIENCE, DELTAGEN shall provide * * * reports to ROCHE
BIOSCIENCE concerning maintenance and care of the Knockout Mice.

3.       PAYMENTS AND BUDGET.

         3.1      BUDGET. ROCHE BIOSCIENCE shall pay to DELTAGEN the payments
set forth in the Budget for each Knockout Mice Project. Except as set forth
in Section 3.2, such payments shall constitute full payment for such Knockout
Mice Project, including all labor, materials and overhead and ROCHE
BIOSCIENCE shall have no other payment obligations hereunder. All payments
made by ROCHE BIOSCIENCE under this Agreement shall be made in accordance
with the Budget.

         3.2      CHANGES TO BUDGET. Upon DELTAGEN's receipt of a Proposed
Change in accordance with Section 2.8, if such Proposed Change is acceptable
to DELTAGEN, ROCHE BIOSCIENCE and DELTAGEN shall negotiate in good faith a
revised Budget (based upon the pricing and standards set forth in Attachment
II) and

* * * Confidential material redacted and separately filed with the Commission.

                                       4
<PAGE>

milestones based on the revised Scope of Work. No such revised Budget or
schedule shall be effective until mutually agreed to in writing by both ROCHE
BIOSCIENCE and DELTAGEN.

         3.3      PAYMENTS. For each Knockout Mice Project, DELTAGEN shall
submit invoices to ROCHE BIOSCIENCE upon DELTAGEN's completion of each
Milestone set forth in the Scope of Work. ROCHE BIOSCIENCE shall pay such
invoices within thirty (30) days after receipt. Invoices based on
accomplishment of Milestones shall include a written representation of
DELTAGEN's completion of such Milestones in compliance with the terms of this
Agreement and, where applicable, documentation showing such completion.

4.       RIGHTS TO INVENTIONS.

         4.1      DELTAGEN'S INVENTIONS. DELTAGEN shall own all Inventions
relating to the design, creation, development, generation or production of
Knockout Mice under this Agreement, excluding any Roche Bioscience Technology.

         4.2      ROCHE BIOSCIENCE'S INVENTIONS. ROCHE BIOSCIENCE shall own
all Inventions relating to the genes and sequences submitted to DELTAGEN by
ROCHE BIOSCIENCE under this Agreement, excluding any Deltagen Technology.

         4.3      KNOCKOUT MICE OWNERSHIP. With respect to each Knockout Mice
Project, after ROCHE BIOSCIENCE has made all applicable Milestone payments or
other payments under this Agreement to DELTAGEN for such Knockout Mice
Project pursuant to Section 3.3, ROCHE BIOSCIENCE shall own (a) such Project
Knockout Mice and all progeny of such Project Knockout Mice, regardless of
whether they are bred to other mice and (b) all phenotypic characteristics of
such Project Knockout Mice and all Data and results generated by DELTAGEN in
performing the Knockout Mice Project for such Project Knockout Mice. DELTAGEN
may not at any time disclose or transfer to a third party any Knockout Mice
owned by ROCHE BIOSCIENCE or that are the subject of this Agreement. DELTAGEN
grants ROCHE BIOSCIENCE the exclusive right to use the Project Knockout Mice,
and their progeny, for any purpose, without restriction, including, but not
limited to, research, development, production, breeding, sales and
distribution of the Project Knockout Mice to its Affiliates and third
parties. Notwithstanding anything to the contrary in this Agreement, ROCHE
BIOSCIENCE shall not use the Project Knockout Mice or any Data, results or
other information provided by DELTAGEN to ROCHE BIOSCIENCE directly or
indirectly to reverse-engineer or practice (and ROCHE BIOSCIENCE shall not
directly or indirectly acquire rights to) any of DELTAGEN's or its licensor's
methods, processes, techniques, inventions, know-how or intellectual property
rights relating directly or indirectly to the design, creation, development,
generation or production of Knockout Mice or transgenic animals.

         4.4      GENE SEQUENCES. DELTAGEN shall not use the gene sequences
transferred by ROCHE BIOSCIENCE, * * * or to reverse-engineer or practice the
methods, processes, techniques, inventions or know-how relating directly or
indirectly to the design, creation, development, generation or production of
such sequences or genes. Such sequences shall be used by DELTAGEN only for
purposes of its work pursuant to this Agreement and may not be transferred or
disclosed by DELTAGEN to any third party other than to fulfill its
obligations pursuant to this Agreement.

         4.5      NO OTHER TECHNOLOGY RIGHTS. Except as otherwise expressly
provided in this Agreement, under no circumstances shall a Party, as a result
of this Agreement, obtain any ownership interest or other right or license in
any technology, information, know-how, patents, pending patent applications,
products or materials of the other Party, including items owned, controlled
or developed by the other Party or transferred by the other Party to
the-first Party at any time pursuant to this Agreement.

         4.6      FURTHER ACTIONS. Each party shall reasonably (a) provide
the other party with such information reasonably available to such party, and
(b) execute and deliver such instruments, in each case, to assist in
perfecting each respective party's patent and intellectual property rights to
Inventions under Sections 4.1, 4.2 and 4.3 above.

* * * Confidential material redacted and separately filed with the Commission.

                                       5
<PAGE>

5.       CONFIDENTIALITY.

         5.1      CONFIDENTIAL INFORMATION. Except as otherwise expressly
provided in this Agreement, each Party shall maintain in confidence the
Confidential Information of the other Party for a period of eight (8) years.
Neither Party shall use, disclose or grant the use of the other's
Confidential Information except on a need-to-know basis to those directors,
officers, employees, Affiliates, agents, sublicensees and permitted
assignees, to the extent such disclosure is reasonably necessary in
connection with its activities as expressly authorized by this Agreement. To
the extent that disclosure is authorized by this Agreement, prior to
disclosure, the Party wishing to disclose the other's Confidential
Information shall obtain the written agreement of any such Person who is not
otherwise bound by confidentiality obligations at least as restrictive as the
obligations set forth in this Agreement, to hold in confidence and not make
use of the Confidential Information for any purpose other than those
permitted by this Agreement. Each Party shall notify the other upon discovery
of any unauthorized use or disclosure of that Party's Confidential
Information.

         5.2      PERMITTED DISCLOSURES. The nonuse and nondisclosure
obligations contained in this Article 5 shall not apply to the extent that
(a) the Receiving Party is required to disclose information by law, order or
regulation of a governmental agency or a court of competent jurisdiction,
PROVIDED THAT, the Receiving Party shall notify the Disclosing Party prior to
any such disclosure to permit the Disclosing Party to oppose such disclosure
or to seek confidential treatment of such information); or (b) the Receiving
Party can demonstrate that (i) the information was public knowledge at the
time of such disclosure by Receiving Party, or thereafter became public
knowledge, other than as a result of acts attributable to Receiving Party in
violation hereof; or (ii) the information was rightfully known by the
Receiving Party (as shown by its written records) prior to the date of
disclosure to it by the Disclosing Party; or (iii) the information was
disclosed to the Receiving Party on an unrestricted basis from a third party
not under a duty of confidentiality to the Disclosing Party; or (iv) the
information was independently developed by employees or agents of the
Receiving Party without access to the Confidential Information of the
Disclosing Party.

         5.3      TERMS OF THIS AGREEMENT. Neither Party shall disclose any
terms or conditions of this Agreement to any Third Party without the prior
consent of the other Party, except as required by applicable law; PROVIDED
HOWEVER, that either Party may disclose the terms or conditions of this
Agreement to a third party under an obligation of confidentiality to such
Party in connection with a proposed sale or in the event of a proposed
merger, change in control, consolidation or other similar transaction.
Notwithstanding the foregoing, prior to execution of this Agreement, ROCHE
BIOSCIENCE and DELTAGEN shall agree upon the substance of information that
can be used to describe the existence and/or terms of this transaction in a
press release and ROCHE BIOSCIENCE and DELTAGEN may disclose such
information, as modified by mutual agreement from time to time, without the
other Party's consent.

         5.4      NO LICENSE. Except as expressly provided in this Agreement,
nothing herein shall be construed as giving either Party any license, right,
title or interest in or ownership of the other Party's Confidential
Information. Upon termination of this Agreement or a particular Knockout Mice
Project as provided in Article 11, or upon either Party's request, each Party
shall return all Confidential Information of the other Party and/or destroy
any portion of any documents, computer records, notes and other material
retained by such Party which contains the Confidential Information of the
other Party. However, each Party may retain one copy of such Confidential
Information in its legal files to be used only for interpretation of this
Agreement.

6.       REPRESENTATIONS AND WARRANTIES.

         6.1      GENERAL REPRESENTATIONS. Each Party hereby represents and
warrants to the other Party as follows:

                  6.1.1    CORPORATE -EXISTENCE. Such Party is a corporation
duly organized, validly existing and in good standing under the laws of the
state in which it is incorporated.

                  6.1.2    AUTHORIZATION AND ENFORCEMENT OF OBLIGATIONS. Such
Party (a) has the corporate power and authority and the legal right to enter
into this Agreement and to perform its obligations hereunder, and (b) has
taken all necessary corporate action on its part to authorize the execution
and delivery of this Agreement and the performance of its obligations
hereunder. This Agreement has been duly executed and delivered on behalf of
such Party, and constitutes a legal, valid, binding obligation, enforceable
against such Party in accordance with its terms.

                                       6
<PAGE>

                  6.1.3    NO CONSENTS. All necessary consents, approvals and
authorizations of all governmental authorities and other persons required to
be obtained by such Party in connection with this Agreement have been
obtained.

                  6.1.4    NO CONFLICT. The execution and delivery of this
Agreement and the performance of such Party's obligations hereunder (a) do
not conflict with or violate any requirement of applicable laws or
regulations, and (b) do not conflict with, or constitute a default under, any
contractual obligation of it.

         6.2      DELTAGEN TECHNOLOGY. DELTAGEN represents and warrants to
its actual knowledge that DELTAGEN is not aware of any issued third party
patent, patent application or other intellectual property right that would be
infringed by ROCHE BIOSCIENCE's use of the Knockout Mice under this
Agreement. DELTAGEN represents and warrants to its * * * that DELTAGEN (a) is
the sole owner or licensee of the Deltagen Technology and (b) has not granted
to any third party any license or other interest in the Deltagen Technology
which would materially impair DELTAGEN's ability to perform its obligations
under this Agreement. Notwithstanding anything to the contrary in this
Agreement, ROCHE BIOSCIENCE acknowledges and agrees that (x) each gene
sequence of interest to ROCHE BIOSCIENCE has been or will be selected by
ROCHE BIOSCIENCE and ROCHE BIOSCIENCE bears full responsibility for
identifying, selecting and providing DELTAGEN with the specific gene
sequences for each Knockout Mice Project, and consequently, for any Claims
relating to such gene sequences and (y) DELTAGEN's representation and
warranty under this Section 6.2 shall not apply or relate to the
identification, selection or knockout of the specific gene sequences for each
Knockout Mice Project under this Agreement or any Knockout Mice arising from
such gene sequences.

         6.3      ROCHE BIOSCIENCE TECHNOLOGY. ROCHE BIOSCIENCE represents
and warrants to its actual knowledge that Roche is not aware of any issued
third party patent, patent application or other intellectual property right
that would be infringed by DELTAGEN's use of the Roche Bioscience Technology
under this Agreement. ROCHE BIOSCIENCE represents and warrants to its actual
knowledge that Roche (a) is the sole owner or licensee of the Roche
Bioscience Technology and (b) has not granted to any third party any license
or other interest in the Roche Bioscience Technology which would materially
impair DELTAGEN's ability to perform its obligations under this Agreement.

         6.4      LIMITATION OF WARRANTY AND LIABILITY. EXCEPT AS OTHERWISE
EXPRESSLY SET FORTH IN THIS AGREEMENT, DELTAGEN MAKES NO WARRANTIES, EXPRESS
OR IMPLIED, WITH RESPECT TO THE KNOCKOUT MICE GENERATED UNDER THIS AGREEMENT
OR THE KNOCKOUT MICE PROJECTS. DELTAGEN DISCLAIMS ALL WARRANTIES, EXPRESS OR
IMPLIED,. INCLUDING WITHOUT LIMITATION A WARRANTY OF NON-INFRINGEMENT AND THE
IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.
IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR LOSS OF PROFITS OR INCIDENTAL,
SPECIAL OR CONSEQUENTIAL DAMAGES DIRECTLY OR INDIRECTLY ARISING OUT OF THIS
AGREEMENT OR THE RESEARCH, DEVELOPMENT, GENERATION OR USE OF THE KNOCKOUT
MICE UNDER THIS AGREEMENT.

7.       REPORTING.

         DELTAGEN shall deliver via overnight delivery service (or other service
agreed to by the parties) to the ROCHE BIOSCIENCE Representative all reports
required to be delivered in connection with a Knockout Mice Project.

8.       RECORD RETENTION, INSPECTIONS, AND COOPERATION.

         8.1 MAINTENANCE OF DATA. DELTAGEN shall maintain all written Data for a
period of not less than two (2) years. At the expiration of such two (2) year
period, ROCHE BIOSCIENCE, at ROCHE BIOSCIENCE's cost and expense, shall promptly
arrange with DELTAGEN for delivery of such Data to ROCHE BIOSCIENCE or DELTAGEN
may dispose of such written Data sixty (60) days after providing written notice
of the same to ROCHE BIOSCIENCE.

* * * Confidential material redacted and separately filed with the Commission.

                                       7
<PAGE>

         8.2      NOTICE OF REGULATORY ACTION. If a Regulatory Agency or, any
other federal, state or local government authority conducts, or gives notice
of its intent to conduct, an inspection at any Designated Site, or takes any
other regulatory action with respect to a Knockout Mice Project conducted
under this Agreement, then the Party learning thereof shall promptly give the
other Party notice thereof, and each Party shall provide the other with any
information reasonably required in connection therewith.

9.       DATA.

         For each Knockout Mice Project, DELTAGEN shall prepare and submit to
ROCHE BIOSCIENCE or its designee all Data as set forth under the applicable
Scope of Work, but in no event later than thirty (30) business days after (i)
the date of termination of such Knockout Mice Project or (ii) the date on which
ROCHE BIOSCIENCE otherwise requests delivery of the Data.

10.      SUBCONTRACTING AND INDEPENDENT CONTRACTOR.

         10.1     SUBCONTRACTING. ROCHE BIOSCIENCE is aware that certain
Knockout Mice Projects may require DELTAGEN to subcontract to third parties
portions of the work required by a Scope of Work. ROCHE BIOSCIENCE shall be
deemed to have approved such subcontracting on the following terms and
conditions: (i) DELTAGEN shall not be allowed or authorized to make any
representations relating to ROCHE BIOSCIENCE without the prior written
consent of ROCHE BIOSCIENCE; and (ii) such third party subcontractor shall be
subject to the terms and conditions of this Agreement. Prior to
subcontracting any work contemplated by a Knockout Mice Project, DELTAGEN
shall notify ROCHE BIOSCIENCE of the intended third party subcontractor and
ROCHE BIOSCIENCE shall be provided with fourteen (14) days in which to object
to the use of a particular subcontractor. If ROCHE BIOSCIENCE does not object
to the use of a particular subcontractor within such fourteen (14) day
period, DELTAGEN may subcontract such work under the Scope of Work to such
third party subcontractor.

         10.2     INDEPENDENT CONTRACTOR. DELTAGEN shall perform its
obligations under this Agreement as an independent contractor, and NOTHING
CONTAINED herein shall be construed to be inconsistent with that relationship
or status. Neither Party, nor their employees, agents and consultants, shall
be considered employees or agents of the other Party and shall not be
entitled to participate in any of the other Party's benefit plans, programs,
employment policies, or workers' compensation insurance. This Agreement shall
not constitute, create, or in any way be interpreted as a joint venture,
partnership or business organization of any kind. Neither Party shall have
the authority to bind the other Party to any agreement whatsoever. Each Party
shall provide evidence satisfactory to the other Party of the existence of
workers' compensation and employer's liability insurance covering any
personnel of such Party supplied hereunder.

11.      TERM AND TERMINATION.

         11.1     TERM . This Agreement shall begin on the Effective
Agreement Date and remain in full force and effect until the later of (a) two
(2) years after the Effective Agreement Date, or (b) the completion by
DELTAGEN of all Milestones under any applicable Knockout Mice Projects under
this Agreement, unless earlier terminated as provided in this Article 11.

         11.2     TERMINATION BY ROCHE BIOSCIENCE. ROCHE BIOSCIENCE may
terminate this Agreement or a Knockout Mice Project at any time without
cause, upon thirty (30) days prior written notice.

         11.3     TERMINATION BY DELTAGEN.DELTAGEN may terminate a Knockout
Mice Project upon DELTAGEN's identification of an item described in Section
2.4 which would prevent DELTAGEN from completing such Knockout Mice Project
using commercially reasonable efforts.

         11.4     TERMINATION BY EITHER PARTY.

                  11.4.1   MATERIAL DEFAULT. This Agreement or a Knockout
Mice Project may be terminated by either Party upon any material breach of
this Agreement by the other Party, provided that any breaching Party shall

                                       8
<PAGE>

be given not less than twenty (20) days prior written notice of such breach and
the opportunity to cure such breach during such period.

                  11.4.2   BANKRUPTCY. This Agreement or a Knockout Mice
Project may be immediately terminated by either Party if the other Party is
dissolved or liquidated, makes a general assignment for the benefit of its
creditors, or files or has filed against it, a petition in bankruptcy or has
a receiver appointed for a-substantial part of its assets.

         11.5     RIGHTS AND OBLIGATIONS AFTER NOTICE OF TERMINATION.

                  11.5.1   TERMINATION BY ROCHE BIOSCIENCE WITHOUT CAUSE OR
FOR BREACH OR BANKRUPTCY OF ROCHE BIOSCIENCE. If this Agreement or a Knockout
Mice Project is terminated by ROCHE BIOSCIENCE pursuant to Section 11.2 or
terminated by DELTAGEN pursuant to Section 11.4, DELTAGEN shall cease further
work on applicable Knockout Mice Projects as immediately as practicable in
accordance with its responsibilities under this Agreement and applicable
Laws, in order to reduce or eliminate further costs, and to cancel, if
permitted under the terms of applicable agreements, any third party
obligations. Within thirty (30) days after DELTAGEN's ceasing of work on such
Knockout Mice Projects, DELTAGEN shall provide ROCHE BIOSCIENCE with a
written itemized statement of all work performed by it through termination,
including any non-cancelable costs or expenses incurred by DELTAGEN prior to
termination. DELTAGEN shall invoice ROCHE BIOSCIENCE for all unpaid
Milestones completed by DELTAGEN and if such notice is received by DELTAGEN
prior to DELTAGEN's completion of work under a Milestone, DELTAGEN shall in
addition have the right to further invoice ROCHE BIOSCIENCE for payment of
such one uncompleted Milestone as if DELTAGEN had completed such Milestone.
DELTAGEN shall deliver to ROCHE BIOSCIENCE all deliverables prepared or
completed by DELTAGEN at the time of such cessation of work and all unused
Study Materials and Data.

                  11.5.2   TERMINATION BY ROCHE BIOSCIENCE FOR BANKRUPTCY OF
DELTAGEN OR BY DELTAGEN FOR DELTAGEN'S INABILITY TO COMPLETE MILESTONE. If
this Agreement or a Knockout Mice Project is terminated by DELTAGEN pursuant
to Section 11.3 or by ROCHE BIOSCIENCE pursuant to Section 11.4.2 above,
DELTAGEN shall deliver all deliverables prepared or completed by DELTAGEN at
the time of such termination, all unused Study Materials and all Data to
ROCHE BIOSCIENCE within sixty (60) days of receipt by DELTAGEN of notice of
termination. DELTAGEN shall provide ROCHE BIOSCIENCE with a written itemized
statement of all work performed by DELTAGEN through the date of termination
(including any Milestones completed by DELTAGEN) and ROCHE BIOSCIENCE shall
pay such invoiced amount within thirty (30) days of receipt of such statement.

                  11.5.3   TERMINATION BY ROCHE BIOSCIENCE FOR BREACH BY
DELTAGEN. If this Agreement or a Knockout Mice Project is terminated by ROCHE
BIOSCIENCE pursuant to Section 11.4.1 above, DELTAGEN shall deliver all
deliverables prepared or completed by DELTAGEN at the time of such
termination, all unused Study Materials and all Data to ROCHE BIOSCIENCE
within sixty (60) days of receipt by DELTAGEN of notice of termination.
DELTAGEN shall provide ROCHE BIOSCIENCE with a written itemized statement of
all work performed by DELTAGEN through the date of termination (including any
Milestones completed by DELTAGEN) and ROCHE BIOSCIENCE shall pay such
invoiced amount (or portion thereof that is not reasonably the subject of
such breach) within thirty (30) days of receipt of such statement.

         11.6     EFFECT OF EXPIRATION OR TERMINATION. Expiration or
termination of this Agreement shall not relieve the parties of any obligation
accruing prior to such expiration or termination. The provisions of Articles
4, 5, 6.4 and 12 shall survive any expiration or termination of this
Agreement.

12.      INDEMNIFICATION.

         12.1     ROCHE BIOSCIENCE'S INDEMNIFICATION. ROCHE BIOSCIENCE shall
defend, indemnify and hold harmless DELTAGEN and its directors, officers,
employees and agents from and against any and all losses, liabilities,
damages or expenses (collectively, "Liabilities") that they may suffer as a
result of any claims, demands, actions or other proceedings (collectively,
"Claims") made or instituted by any third party and arising out of or
relating to (a) a breach of any representation, warranty or covenant of ROCHE
BIOSCIENCE under this Agreement or (b) ROCHE BIOSCIENCE's gross negligence or
willful misconduct, except in each case to the extent such Liabilities
resulted from the gross negligence or willful misconduct of DELTAGEN.

                                       9
<PAGE>

         12.2     DELTAGEN'S INDEMNIFICATION. DELTAGEN shall defend,
indemnify and hold harmless ROCHE BIOSCIENCE and its directors, officers,
employees and agents from and against any and all Liabilities that they may
suffer as a result of any Claims made or instituted by any third party and
arising out of or relating to (a) a breach of any representation, warranty or
covenant of DELTAGEN under this Agreement or (b) DELTAGEN's gross negligence
or willful misconduct, except in each case to the extent such Liabilities
resulted from the gross negligence or willful misconduct of ROCHE BIOSCIENCE.

         12.3     PROCEDURE. A Party (the "Indemnified Party") which intends
to claim indemnification under this Article 12, shall promptly notify the
other Party (the "Indemnifying Party") of any Claim with respect to which the
Indemnified Party intends to claim such indemnification. The Indemnifying
Party shall assume and control the defense of such Claim with counsel
selected by the Indemnifying Party; PROVIDED, HOWEVER, that the Indemnified
Party shall have the right to retain its own counsel, with the fees and
expenses to be paid by the Indemnifying Party if representation of the
Indemnified Party by the counsel retained by the Indemnifying Party would
create a conflict for the interests of the Indemnified Party. The indemnity
obligations under this Article 12 shall not apply to amounts paid in
settlement of any Liability if such settlement is effected without the
consent of the Indemnifying Party, which shall be given or not in the
Indemnifying Party's sole discretion. The failure to deliver notice to the
Indemnifying Party within a prompt time after the commencement of any such
action, if prejudicial to its ability to defend such action, shall relieve
the Indemnifying Party of any liability to the Indemnified Party under this
Article 12, but the omission so to deliver notice to the Indemnifying Party
will not relieve it of any liability that it may have to the Indemnified
Party otherwise than under this Article 12. The Indemnifying Party may not
settle the action or otherwise consent to an adverse judgment in such action
that diminishes the rights or interests of the Indemnified Party without the
express written consent of the Indemnified Party. The Indemnified Party, its
employees and agents, shall cooperate fully with the Indemnified Party and
its legal representatives in the investigation of any Claim covered by this
indemnification.

13.      TAXATION.

         In order that ROCHE BIOSCIENCE may comply with applicable tax laws and
regulations, DELTAGEN, at ROCHE BIOSCIENCE's cost and expense, if reasonably
requested by ROCHE BIOSCIENCE, agrees to provide within thirty (30) days after
the close of each calendar year such non-confidential information reasonably
available to DELTAGEN which ROCHE BIOSCIENCE reasonably requests and deems
necessary to properly compute its tax liability. In order to assist DELTAGEN in
providing such information, ROCHE BIOSCIENCE shall provide DELTAGEN with a
summary of payments made to it during such year for research activities
conducted during such year.

14.      TRADEMARKS.

         Neither Party shall use of the trademarks or tradenames of the other
Party without the express written consent of the other Party.

15.      DELAYS OR FORCE MAJEURE.

         15.1     FORCE MAJEURE. Neither Party shall be liable for the
failure to perform its obligations under this Agreement or a Knockout Mice
Project if such failure is occasioned by a contingency beyond such Party's
reasonable control, including but not limited to strikes or other labor
disturbances, lockouts, riots, wars, fires, floods, earthquakes or storms. A
Party claiming a right to excused performance under this Section 15.1 shall
immediately notify the other Party in writing of the extent of its inability
to perform, which notice shall specify the occurrence beyond its reasonable
control that prevents such performance.

         15.2     DELAY. If ROCHE BIOSCIENCE delays the actual start of a
Knockout Mice Project for any reason, the date by which DELTAGEN is obligated
to complete its duties and obligations as described in the applicable Scope
of Work shall be extended by the number of days the start was delayed.

                                       10
<PAGE>

16.      NOTICES.

         Any notice-required or permitted to be given hereunder shall be deemed
sufficient if sent by facsimile letter or overnight courier, or delivered by
hand to ROCHE BIOSCIENCE or DELTAGEN at (i) in the case of notices pursuant to
this Agreement, the respective addresses set forth below or at such other
address as either Party hereto may designate. If sent by facsimile letter,
notice shall be deemed given when the TRANSMISSION IS completed if the sender
has a confirmed transmission report. If a confirmed transmission report does not
exist, then the notice shall be deemed given when the notice is actually
received by the person to whom it is sent. If delivered by overnight courier,
notice shall be deemed given when it has been signed for. If delivered by hand,
notice shall be deemed given when received. Any notice sent by facsimile must
also be sent by mail or overnight courier or delivered by hand.

IF TO DELTAGEN:
Deltagen, Inc.
* * *

Fax:     (650) 610-6823
Attn:    William Matthews
President

IF TO ROCHE BIOSCIENCE:
Roche Bioscience, a Division of Syntex (U.S.A.) Inc.
3401 Hillview Avenue
Palo Alto, CA 94304
Fax: (650) 852-1932
Attn: Business Development,
Neurobiology Unit., R7-101

With a copy to the above address,
Attn:    Legal Affairs, A2-225
Fax:     (650) 852-1338

17.      MISCELLANEOUS PROVISIONS.

         17.1     ASSIGNMENT AND SUBCONTRACTING. Neither Party may assign
this Agreement to any third party without the prior written consent of the
other Party, PROVIDED HOWEVER, that either Party may, without such consent,
assign this Agreement and its rights and obligations hereunder in connection
with the transfer or sale of all or substantially all of its business, or in
the event of its merger, consolidation, change in control or similar
transaction. Any permitted assignee shall assume all obligations of its
assignor under this Agreement.

         17.2     AMENDMENTS. No provision of this Agreement, the Budget or
the Scope of Work may be amended, revoked, or waived except in writing signed
and delivered by an authorized officer of each Party. Either Party's failure
to require the other Party to comply with the provisions of this Agreement
shall not be deemed a waiver of such provision or any other provision of this
Agreement.

         17.3     VALIDITY. If any clause, section or paragraph of this
Agreement is determined by a court of competent jurisdiction to be illegal,
invalid or unenforceable, it will be deemed severed from the remainder of
this Agreement and will have no effect on the legality, validity or
enforceability of the remaining provisions.

         17.4     HEADINGS. The paragraph headings of this Agreement are
merely for the convenience of the parties and are not to be construed as
modifying or changing the obligations or conditions expressed in this
Agreement.

         17.5     ENTIRETY. This Agreement represents the entire
understanding as of the Effective Agreement Date hereof between the parties
with respect to the matter hereof, and supersedes all prior agreements,
negotiations; understandings, representations, statements, and writings
between the parties relating thereto.

* * * Confidential material redacted and separately filed with the Commission.

                                       11
<PAGE>

         17.6     CONFLICT WITH SCOPE OF WORK OR BUDGET. If any terms of this
Agreement are in conflict with any terms of any Scope of Work or Budget, the
terms of this Agreement shall govern.

         17.7     COUNTERPARTS. This Agreement may be executed in several
counterparts, each of which shall be deemed an original but all of which
shall. constitute one and the same instrument.

         17.8     GOVERNING LAW. This Agreement shall be governed by and
construed in accordance with the laws of the State of California, without
regard to the conflicts of law principles of California or any other state or
jurisdiction.

         IN WITNESS WHEREOF, the Parties hereto through each of their respective
duly authorized representatives have caused this Agreement to be executed as of
the Effective Date.

<TABLE>
<S>                                                           <C>
ROCHE BIOSCIENCE DIVISION OF SYNTEX (U.S.A.) INC.             DELTAGEN, INC

By                                                            By
     /s/ R.L. WHITING                                              /s/ WILLIAM MATTHEWS
     -------------------------------------------------             -------------------------------------------------

Name:                                                         Name:
        R.L. WHITING                                                   WILLIAM MATTHEWS
        ----------------------------------------------                 ---------------------------------------------
Title:  SUP, HEAD, NEUROBIOLOGY                               Title:   PRESIDENT

Date:                                                         Date:
          8/2/98                                                       9/30/98
          --------------------------------------------                 ---------------------------------------------
</TABLE>

                                       12
<PAGE>

                                  ATTACHMENT I

                              FORM OF SCOPE OF WORK

         1.       Each Knockout Mice Project shall be conducted according to
the general terms and conditions contained in this Scope of Work, the
following specifications contained herein and the provisions of the Master
Services Agreement between the parties. The Roche Bioscience Representative
shall be * * *. The parties shall agree in writing upon any additional
specific terms and conditions for each Scope of Work prior to the
commencement of each respective Knockout Mice Project.

         Each Knockout Mice Project shall involve a knockout of * * * gene of
interest to ROCHE BIOSCIENCE. The first * * * genes-of interest for knockout
(each corresponding to a separate Knockout Mice Project) to ROCHE BIOSCIENCE are
listed below. ROCHE BIOSCIENCE shall have the option of expanding the number of
Knockout Mice Projects (and thus, the number of genes of interest) up to a total
number of * * * Knockout Mice Projects (and genes of interest), by providing
written notice to DELTAGEN during the term of this Agreement. The parties shall
mutually agree upon the Scope of Work for such genes.

Genes    of Interest:

         * * *

2.       The following Milestones shall apply to each Knockout Mice Project

<TABLE>
<CAPTION>
         --------- ---------------------------------------------- ---------------------------------------------------
                   Milestone                                      Completion Date
         --------- ---------------------------------------------- ---------------------------------------------------
<S>                <C>                                            <C>
         1.        * * *                                          * * * from Effective Commencement Date
         --------- ---------------------------------------------- ---------------------------------------------------
         2.        * * *                                          * * * from Effective Commencement Date
         --------- ---------------------------------------------- ---------------------------------------------------
         3.        * * *                                          * * * from Effective Commencement Date
         --------- ---------------------------------------------- ---------------------------------------------------
</TABLE>

Milestone 1:      * * *

         DELTAGEN will * * * based on * * * received from ROCHE BIOSCIENCE.
Anticipated time frame for completion will be within * * * after receipt of
necessary * * *. In the event of unforeseen technical difficulties occurring
within * * * of initiating * * * resulting from the * * *, DELTAGEN (upon
consultation with ROCHE BIOSCIENCE) may * * * at * * *, or ROCHE BIOSCIENCE
may terminate the Knockout Mice Project with no obligation to pay Milestone
1. Irrespective of the number of * * *, there will be * * * Milestone 1
payment for the * * * for each * * *, unless a * * * is-selected because of *
* * in Milestone 2, in which case * * *.

Milestone 2:      * * *

         DELTAGEN will * * * and * * * and * * *. DELTAGEN will * * * a
maximum of * * * for * * * of at least * * * and up to a maximum * * * in
fulfillment of this Milestone 2. If * * * is identified by DELTAGEN and ROCHE
BIOSCIENCE requests DELTAGEN to identify additional * * *, or if * * * is the
* * *, DELTAGEN, after consultation with ROCHE BIOSCIENCE, will either (a) *
* * and * * * with the * * * and * * * or (b) * * *, in each case at the
"Additional Payment" rates set forth in the Budget. Alternatively, ROCHE
BIOSCIENCE may terminate this Knockout Mice Project without any further
obligation to DELTAGEN. The anticipated time for completion of * * * the * *
* will be * * * from the Effective Commencement Date* * *. ROCHE BIOSCIENCE
will also receive * * * in order to confirm * * * to confirm the * * *, as
well as * * *, * * *.

* * * Confidential material redacted and separately filed with the Commission.

                                       13
<PAGE>

Milestone 3:      * * *

         DELTAGEN will transfer a minimum of * * * and up to a maximum of * * *
independent * * * will be transferred only if * * * clones happen to be * * *
by DELTAGEN in the * * * of the * * * in Milestone 2) into * * * to
generate * * * mice (dependent upon the * * *).

         DELTAGEN shall inform ROCHE BIOSCIENCE as to what * * * was used,
what * * *. Anticipated time frame for completion will be * * * from the
Effective Commencement Date. DELTAGEN will provide to ROCHE BIOSCIENCE by
delivery FOB ROCHE BIOSCIENCE's designated carrier, * * * mice (* * *), with
* * * from at least * * * of the * * *. Such * * * shall be reasonably and
promptly confirmed by ROCHE BIOSCIENCES using * * *. ROCHE BIOSCIENCE shall
use commercially reasonable and good scientific practices in undertaking * *
*. If the * * * reasonably demonstrates that * * * has occurred with the * *
* mice provided by DELTAGEN to ROCHE BIOSCIENCE, DELTAGEN shall provide to
ROCHE BIOSCIENCE by delivery FOB ROCHE BIOSCIENCE's designated carrier * * *,
PROVIDED THAT, ROCHE BIOSCIENCE has reasonably and properly conducted * * *.
Prior to DELTAGEN providing such additional * * * mice, ROCHE BIOSCIENCE
shall demonstrate to DELTAGEN's reasonable satisfaction that * * *.

* * * Confidential material redacted and separately filed with the Commission.

                                       14
<PAGE>

                             ATTACHMENT II (BUDGET)                [PAGE 1 of 2

                           PREFERRED PRICING SCHEDULE

         Total cost for each Knockout Mice Project through * * *

         STANDARD MUTATIONS AND STANDARD PROCEDURES:

The following pricing schedule in this Budget is based upon a total of * * *
Knockout Mice Projects (* * * gene sequences-of interest to ROCHE BIOSCIENCE).
If ROCHE BIOSCIENCE requests DELTAGEN to perform more than * * * Knockout Mice
Projects, the parties shall negotiate and agree in good faith upon a revised
payment schedule for each additional Knockout Mice Project performed after the
tenth Project.

         THE FOLLOWING MILESTONE PAYMENT SCHEDULE SHALL APPLY TO EACH KNOCKOUT
MICE PROJECT:

<TABLE>
<CAPTION>
---------------- ---------------------------------- ------------------------------------- ----------------------------
                                                    DELIVERABLE (MUST MEET FULL
                                                    DESCRIPTIONS IN ATTACHMENT I UNLESS
                 MILESTONE                          OTHERWISE PROVIDED)                   PAYMENT
---------------- ---------------------------------- ------------------------------------- ----------------------------
<S>              <C>                                <C>                                   <C>
0.               * * *                              No additional requirements under                           $13,000
                                                    Attachment I; to be paid by ROCHE
                                                    BIOSCIENCE within 30 days of
                                                    Effective Commencement Date
---------------- ---------------------------------- ------------------------------------- ----------------------------
1.               * * *                              Notification from DELTAGEN to ROCHE                         * * *
                                                    BIOSCIENCE of successful completion
                                                    of Milestone I
---------------- ---------------------------------- ------------------------------------- ----------------------------
2.               * * *                              DELTAGEN's * * * of initial                                 * * *
                                                    * * * colonies for * * *
---------------- ---------------------------------- ------------------------------------- ----------------------------
3.               * * *                              Successful generation and delivery                          * * *
                                                    FOB to ROCHE BIOSCIENCE's
                                                    designated carrier of * * * for at
                                                    least * * *
---------------- ---------------------------------- ------------------------------------- ----------------------------
</TABLE>

* * * Confidential material redacted and separately filed with the Commission.

                                       15
<PAGE>

                              (ATTACHMENT II (BUDGET))             [PAGE 2 of 2]

<TABLE>
<CAPTION>
         ADDITIONAL PAYMENTS:

---------------------------------------- -------------------------------------- --------------------------------------
MILESTONE                                TASK DESCRIPTION                       PAYMENT TERMS
---------------------------------------- -------------------------------------- --------------------------------------
<S>                                      <C>                                    <C>
2a.  * * *                               Construction of * * * , and * * *      Not to exceed $* * *, negotiated on
                                         of the * * * colonies.                 a case-by-case basis, for the
                                                                                combined achievement of selecting a
                                                                                * * * and * * * up to * * *
---------------------------------------- -------------------------------------- --------------------------------------
2b.  * * *                               * * * of additional * * *              $* * * per each * * *
                                         following * * * of * * *.
---------------------------------------- -------------------------------------- --------------------------------------
</TABLE>

* * * Confidential material redacted and separately filed with the Commission.

                                       16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]